Up 42% since January: Why Merck is defeating the patent cliff Harry Jones Wed, November 11, 2026 at 4:16 AM EST 4 min read MRK -0.77% BMY -0.53% PFE -0.44% ^DJI -0.30% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Investing.com and Yahoo Finance LLC may earn commission or revenue on some items through the links below.
Investing.com — Large-cap pharmaceutical stocks have spent much of the year under heavy pressure as investors brace for patent expirations on cornerstone treatments. The center of that anxiety has been the 2028 loss of exclusivity for Keytruda, the world's top-selling oncology drug, which has kept sentiment subdued across peers like Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE).
Yet Merck & Co. (NYSE:MRK) has completely decoupled from sector skepticism, advancing 42.3% since January to trade near $146.73. While headline debates treat patent expirations as sudden financial cliffs, Merck's operating results show a business systematically neutralizing the revenue headwind years before it arrives.
Spotting when market anxiety obscures commercial pipeline execution is what InvestingPro's ProPicks AI models look for. The system added Merck to the Dominate the Dow strategy in January at $103.13. In November's active portfolio, Merck is paired with resilient blue chips—including an industrial power generation titan, a commercial oncology biopharma developer, and an essential national telecom provider.
Review the Dow stocks the AI screen picked for November: Explore the Dominate the Dow strategy on InvestingPro
Converting a patent cliff into an extended transition
Third-quarter financial results confirmed why institutional capital has backed the drugmaker. Merck delivered revenue of $18.1 billion against consensus expectations of $17.28 billion, and adjusted earnings per share of $2.49 against $2.09, prompting management to raise full-year 2026 revenue guidance to between $66.8 billion and $67.3 billion.
Keytruda continued to expand, with sales rising 6% year-over-year to $8.6 billion. Crucially, Merck is actively restructuring the franchise's lifespan. Keytruda Qlex, a subcutaneous formulation administered as an injection rather than a multi-hour intravenous infusion, extends patent protections well into the 2030s. Management is targeting 30% to 40% U.S. patient conversion by the end of 2027, turning an abrupt revenue cliff into a manageable transition.
New therapeutic blockbusters are accelerating alongside it. Winrevair, an essential therapy for pulmonary arterial hypertension, surged 94% year-over-year to $694 million in the quarter, reinforced by an expanded FDA label supporting earlier clinical intervention. In oncology, the personalized cancer vaccine intismeran—developed in partnership with Moderna—cut the risk of melanoma recurrence or death by 42% alongside Keytruda in Phase 3 trials, setting up a planned regulatory filing for 2027. Supported by these launches, management expects consolidated revenues to surpass $70 billion by the mid-2030s.
Valuation, cash conversion, and dividend durability
That commercial execution is backed by substantial organic liquidity. Merck generated $18.7 billion in operating cash flow over the trailing twelve months, supporting a 4.07% free cash flow yield that comfortably covers its 2.31% dividend yield. The company has raised its dividend for 15 consecutive years while planning approximately $3 billion in share repurchases for 2026. InvestingPro's Financial Health framework rates Merck as "Good," supported by reliable cash flow coverage over its debt service.
The stock's headline multiple of 52.2 times trailing earnings reflects a trough year in reported accounting profits. Looking ahead, consensus estimates compiled on InvestingPro show the valuation multiple compressing rapidly to 16.3 times 2027 earnings. While management projects more than $2 billion in 2027 revenue headwinds from legacy generic competition, the underlying pipeline provides substantial earnings support.
Wall Street analysts share that constructive stance. The median price target sits at $161.53, implying double-digit upside from current trading levels, with top-tier targets from JPMorgan reaching $175 and Morgan Stanley at $174 following third-quarter results.
Investors can review subcutaneous Keytruda conversion timelines, Winrevair market launch trajectories, and dividend payout coverage inside the Merck Pro Research Report.
Follow Merck's Keytruda conversion and dividend coverage: Access the Merck Pro Research Report on InvestingPro
Looking beyond pharmaceutical patent anxiety
Merck's 42% advance demonstrates why patent expirations do not automatically derail high-margin businesses. By developing subcutaneous delivery methods, securing new blockbuster approvals, and generating $18.7 billion in operating cash flow, the company has transformed a projected revenue cliff into a durable runway.
Identifying resilient businesses before market sentiment normalizes is the objective of InvestingPro's data-driven strategies. The Dominate the Dow portfolio evaluates balance sheets every month, systematically allocating capital toward market leaders with protected moats and verified cash flow across essential industries.
For investors seeking high-conviction ideas in the active November portfolios, full access to all ProPicks AI strategies costs just $9 a month.
Get the latest picks across every ProPicks AI strategy Right now, Yahoo Finance users get a special 60% off InvestingPro
Disclosure: The author holds no position in the stocks mentioned. Data and financial metrics as of November 10, 2026.
Up 42% since January: Why Merck is defeating the patent cliff
SoftBank shares tumble after $7 bln quarterly loss
Nasdaq futures jump on CoreWeave earnings; hot CPI reinforces Fed hike bets
